XAXavier Armoiry

Xavier Armoiry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xavier Armoiry has a total of 279 co-authors. Here are the top co-authors by number of shared publications:

  • Martin Connock

    University of Birmingham, Centre for Evidence and Implementation Science (CEIS), Health Services Management Centre School of Social Policy and Society, College of Social Sciences , Birmingham

    14 shared publications
  • G. Aulagner

    Hospices Civils De Lyon, Groupement Hospitalier Est, Service Pharmaceutique/UMR-CNRS 5510/MATEIS, Bron, France

    11 shared publications
  • Peter Auguste

    Warwick Medical School, University of Warwick, Coventry, UK

    7 shared publications
  • Aileen Clarke

    Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

    6 shared publications
  • Benjamin Gory

    Department of Diagnostic and Therapeutic Neuroradiology, CHRU-Nancy, Nancy, France

    6 shared publications
  • Jean-François Obadia

    Hopital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation Cardiaque, Hospices Civils de Lyon and Claude Bernard University, Lyon, France

    6 shared publications

Latest Publications

  • Open Access

    Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial

    by Apolline Grangeon, Martin Connock, Peter Auguste, Jean François Obadia, Maurice Enriquez-Sarano, Benjamin Essayagh, Xavier Armoiry

    Introduction: The Evoque™ transcatheter tricuspid valve replacement (TTVR) system demonstrated superiority over optimal medical treatment (OMT) in the TRISCEND II trial. We aimed to evaluate the cost-effectiveness of TTVR in patients with severe Tricuspid Regurgitation (TR) from the French healthcare perspective. Methods: A state-transition Markov model was developed to assess the cost-effectiveness of Evoque™ TTVR versus OMT alone over a lifetime horizon. The modelled cohort reflected the TRISCEND II population. Health states were defined by TR severity (none/trace, mild, moderate, severe) and death. Transition probabilities, adverse events, and hospitalization rates were informed by TRISCEND II. Long-term survival outcomes were extrapolated by TR severity using published data. Utilities were estimated from the NYHA class distribution. Costs and health outcomes were discounted at 2.5% annually. Results: Evoque™ was associated with an incremental 1.76 life-years gained (LYG) and 1.63 quality-adjusted LYG (QALY). Incremental costs were €39 382 driven by device acquisition and procedure costs, resulting in an incremental cost-effectiveness ratio (ICERs) of €22 327/LYG and €24 109/QALY gained. Assuming no mortality difference in extrapolations, the ICER would increase to €86 428/QALY (+258%). The model was highly sensitive to assumptions on time horizon, utility, discount rate, and post-trial mortality extrapolation, leading to major uncertainty. Conclusion: Evoque™ may represent a cost-effective strategy in severe TR patients; however, this should be interpreted with caution, as results rely heavily on extrapolated data and are subject to high structural and parameter uncertainty. The projected long-term benefits are largely model driven rather than empirically demonstrated, emphasizing the need for extended follow-up data.

  • Open Access

    Assessing the adequacy of funding for robotic-surgery hospital stays: a focused cost analysis based on 1,722 procedures in a French university hospital

    by Arthur Lacassagne, Solène Molle, Lionel Badet, Pierre-Adrien Bolze, Marc Colombel, Fréderic Hameury, Jean-Michel Maury, Arnaud Pasquer, Charles-André Philip, Alain Ruffion, et al.

    Context: Robotic-assistance is increasingly used in French hospitals and funded through standard Diagnosis-Related Group (DRG) tariffs. We evaluated the actual costs of robotic-assisted surgical procedures (RASP) and compared these with hospital revenues to assess whether current funding levels are sufficient to cover procedural costs. Materials and methods: This cross-sectional study was conducted in Lyon University Hospitals (France). We examined all RASP performed over January 2023-June 2024. We matched medical device usage data from the DaVinci system manufacturer’s database with the hospital database, calculated related costs, and compared these against the costs/ tariffs of DRGs using the national cost benchmarks. Results: Based on a final sample of 1,722 procedures, we observed substantial cost variations between surgeries for RASP-specific medical devices, with higher-cost procedures such as those requiring staplers/ reloads (mean costs: €2,858 to €3,189) and lower-cost procedures (€1,207 to €1,621). Among the 21 most frequently performed surgeries, the mean length of stay (LoS) was numerically lower than national benchmarks in 20 cases. Fourteen were associated with mean costs of RASP devices exceeding the national benchmark within the same cost category (medical consumables) (range of additional cost: +€309 to +€2,428); incorporating potential savings resulting from reduced LoS could offset these additional costs in three cases. Medical consumable costs were lower for five surgeries (range of cost reduction: -€109 to -€726). Conclusions: In most cases, hospital funding based on current DRG tariffs is insufficient to cover the actual costs of RASP, suggesting that these stays are undervalued even though a reduced LoS may partially offset the additional costs.


  • Open Access

    Cost-effectiveness of percutaneous mitral repair for patients with severe secondary mitral regurgitation: an updated evaluation using a modelling approach based on COAPT final data after 5-year follow-up

    by Martin Connock, Peter Auguste, Jean-François Obadia, Xavier Armoiry

    Objectives To evaluate the cost-effectiveness of percutaneous repair (PR) for secondary mitral regurgitation. Design An economic evaluation using a time-varying Markov model comprising three states to assess the cost and effectiveness of PR added to guideline-directed medical treatment (GDMT) compared with GDMT alone. Clinical outcomes considered within the model were overall survival and heart failure (HF) hospitalisations (HFH), and the incremental cost-effectiveness ratio (ICER) was calculated. Cost data were derived from a literature search. Sensitivity analyses were undertaken. Setting The French healthcare system perspective assuming a lifetime horizon. Participants Published data at 5 years obtained from patients enrolled in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation study. Results In our base case, we chose cubic spline models to extrapolate overall survival, and we used log-logistic models to estimate cumulative HFH. After discounting, the model generated life-years of 3.843 years and 3.055 years for PR+GDMT and GDMT, respectively. Discounted total quality-adjusted life-year (QALY) values were 2.572 and 1.945 for PR+GDMT and GDMT, respectively (incremental 0.627 QALY). Discounted total costs were €42 709 and €20 732 for the intervention and the control groups, respectively (incremental €21,977), resulting in an ICER of €35,068/QALY. At a threshold of €50 000 per QALY, PR had a 0.85 probability of being cost-effective. Conclusion Updated trial data have enabled investigators to provide a more reliable estimation of the ICER, which suggests that PR has good value for money compared with GDMT alone.


  • Open Access

    How can the reform of the activity-based payment system (T2A) help in financing innovative health products?

    by Xavier Armoiry, Nejma Saidani, Martine Aoustin, Dorothée Camus, Auriane Cano-Chancel, Sophie Carlier, Albane Degrassat-Théas, Anne-Aurélie Epis de Fleurian, Anne Grumblat, Aurélie Lavorel, et al.


  • Open Access

    Comment la réforme de la T2A peut-elle permettre de financer des produits de santé innovants ?

    by Xavier Armoiry, Nejma Saidani, Martine Aoustin, Dorothée Camus, Auriane Cano-Chancel, Sophie Carlier, Albane Degrassat-Théas, Anne-Aurélie Epis de Fleurian, Anne Grumblat, Aurélie Lavorel, et al.


  • Open Access

    Reconciling conflicting evidence in the evaluation of the MitraClip system: Assessment of and response to the MITRA‐FR and COAPT trials by key stakeholders

    by Manuela Montagnon, Yenfu Chen, Amy Grove, Jieun Park, Jean‐François Obadia, Xavier Armoiry


  • Open Access

    Cost-effectiveness of left atrial appendage occlusion during cardiac surgery in France: An economic evaluation based on the LAAOS III study

    by Manon Benmalek, Martin Connock, Léa Savio, Jean-François Obadia, Xavier Armoiry

    Objectives: Left atrial appendage occlusion during cardiac surgery is a therapeutic option for stroke prevention in patients with atrial fibrillation. The effectiveness and safety of left atrial appendage occlusion have been evaluated in several studies, including the LAAOS-III trial. While these studies have demonstrated efficacy and safety, the long-term economic impact of this surgical technique has not yet been assessed. Here, we aimed to evaluate the cost-effectiveness and cost-utility of left atrial appendage occlusion during cardiac surgery over a long-term time horizon. Methods: Our study was based on a model representing an hypothetical cohort with the same characteristics as LAAOS-III trial patients. We modelled the incidence of ischemic strokes and systemic embolisms in each intervention arm: "occlusion" and "no-occlusion," using a one-month cycle length with a 20-year time horizon. Regarding occlusion devices, sutures, staples, or an approved surgical occlusion device (AtriClip™—AtriCure, Ohio, USA) could be used. Results: Our model generated an average cost savings of 607 euros per patient and an incremental gain of 0.062 quality-adjusted life years (QALYs), resulting an incremental cost-utility ratio (ICUR) of €-9,775/QALY. The scenario analysis in which occlusion was systematically performed using the AtriClip™ device generated an ICUR of €3,952/QALY gained. Conclusions: In the base-case analysis, the strategy proved to be more effective and less costly, confirming left atrial appendage occlusion during cardiac surgery as an economically dominant strategy. The scenario analysis also appeared cost-effective, although it did not result in cost savings. This study provides a new perspective on the assessment of the cost-effectiveness of these techniques.


  • Open Access

    Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk

    by Martin Connock, Peter Auguste, Aude Capelle, Anna-Maria Hénaine, Jean-François Obadia, Xavier Armoiry

    Objective To review the survival modelling used in cost-effectiveness studies evaluating an interventional procedure and to discuss implications for decision-makers. Design A case study of three economic evaluations that each used immature data from the EVEREST II High Surgical Risk (HSR) Study of transcatheter edge-to-edge repair (TEER) for patients with severe mitral regurgitation (MR) who were at high risk of surgery. Setting Estimation of patient survival in cost-effectiveness studies. Participants The EVEREST II HSR Study included 78 patients who had TEER of the mitral valve using the MitraClip device and a retrospectively identified control group of 36 patients who received medical management and were followed up for 12 months. Observed survival (TEER arm only) was updated at 5 years. Results Two studies used 12-month observed mortality from EVEREST II HSR to model survival over lifetime horizons. Observed and modelled survival were associated with considerable uncertainty due to short follow-up and small numbers of participants. Modelling control patients’ survival required an approximate 10-fold extrapolation based on 12-month observation of only 38 patients. Observed 5-year survival in the TEER group differed from that less mature follow-up suggesting that survival modelling based on shorter follow-up was unsatisfactory. No public domain data for the control group are available beyond 12-month follow-up so meaningful estimates using mature data for both arms are currently not possible. A third study developed survival models using incompletely reported transitions between MR grades in EVEREST II HSR and mortality rates observed for different MR grades derived from a study in an unrelated population. Conclusions Modelling survival in such small samples followed up for only 12 months is associated with great uncertainty, and cost-effectiveness results based on these analyses should be viewed as premature and used cautiously in reimbursement decisions.